Currently, all cancer types effectively treated by targeted therapy appear to be mono-driver cancers, such as chronic myeloid leukemia dependent on BCR-Abl [59], non-small cell lung cancer dependent on mutated EGFR [60], and gastrointestinal stromal tumors dependent on c-Kit [61]. Here, ABL1 is linked to gastrointestinal stromal tumor.